{"id":"without-concurrent-cisplatin-chemotherapy","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the PD-1 receptor, it prevents cancer cells from evading the immune system, allowing the body's immune cells to attack and destroy the cancer cells.","oneSentence":"This drug targets the PD-1 receptor to inhibit cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:05.250Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":475},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT02973386","phase":"PHASE3","title":"Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients","status":"COMPLETED","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2017-01-13","conditions":"Local Advanced High Risk Nasopharyngeal Carcinoma","enrollment":294},{"nctId":"NCT07381543","phase":"PHASE2","title":"Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03","conditions":"Localized Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT06563479","phase":"PHASE3","title":"A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-08-19","conditions":"HPV-Related Squamous Cell Carcinoma","enrollment":291},{"nctId":"NCT00980954","phase":"PHASE3","title":"Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Cervical Cancer","enrollment":236},{"nctId":"NCT05975307","phase":"PHASE2","title":"Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-01","conditions":"Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy","enrollment":71},{"nctId":"NCT07248670","phase":"PHASE3","title":"Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-04","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":252},{"nctId":"NCT07249021","phase":"","title":"This is a Multicentre International Study Evaluating CT-based IGABT With / Without Either TRUS During BT/Pre BT MR as Per IBS-GECESTRO-ABS Recommendations for Target contouring-as an Alternative to MRIGABT for Cervical Cancer From Implementation Perspectives Under EMBRACE-III:TRIPLET IMPACT Study.","status":"NOT_YET_RECRUITING","sponsor":"Homi Bhabha Cancer Hospital & Research Centre","startDate":"2025-11","conditions":"Locally Advanced Cervical Cancer, Brachytherapy, CT","enrollment":1200},{"nctId":"NCT02918955","phase":"PHASE3","title":"Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2016-12-16","conditions":"Head and Neck Neoplasms","enrollment":65},{"nctId":"NCT06139419","phase":"PHASE2","title":"The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-25","conditions":"Non-small Cell Lung Cancer","enrollment":114},{"nctId":"NCT06281886","phase":"PHASE2","title":"Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-01","conditions":"Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity","enrollment":170},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Head Cancer, Head Cancer Neck","enrollment":40},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT06020885","phase":"PHASE1","title":"Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-08-31","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":18},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT04952480","phase":"PHASE2","title":"Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2022-06-13","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT04634877","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-01-10","conditions":"Endometrial Neoplasms","enrollment":990},{"nctId":"NCT06421376","phase":"PHASE2","title":"Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-01","conditions":"Esophageal Cancer, Immunotherapy, Induction Therapy","enrollment":60},{"nctId":"NCT04223024","phase":"PHASE2","title":"Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-01-31","conditions":"Nasopharyngeal Carcinoma","enrollment":246},{"nctId":"NCT02215265","phase":"PHASE3","title":"Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisette Nixon","startDate":"2015-10","conditions":"Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer","enrollment":1269},{"nctId":"NCT01220583","phase":"PHASE2","title":"Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2011-01","conditions":"Head and Neck Cancer","enrollment":252},{"nctId":"NCT06814067","phase":"PHASE2","title":"Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-02-10","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":80},{"nctId":"NCT05944809","phase":"PHASE2","title":"The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients","status":"COMPLETED","sponsor":"JIANYANG WANG","startDate":"2023-07-20","conditions":"Esophageal Cancer, Intensity-modulated Radiation Therapy, Concurrent Chemoradiotherapy","enrollment":32},{"nctId":"NCT06087614","phase":"PHASE2","title":"Dose Escalation Using Hypoxia-adjusted Radiotherapy","status":"RECRUITING","sponsor":"Rajiv Gandhi Cancer Institute & Research Center, India","startDate":"2024-04-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":124},{"nctId":"NCT06762158","phase":"NA","title":"NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-10-30","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":50},{"nctId":"NCT05255653","phase":"PHASE2, PHASE3","title":"Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2021-11-11","conditions":"Endometrial Cancer","enrollment":1615},{"nctId":"NCT04923906","phase":"PHASE3","title":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-08-11","conditions":"Non-small Cell Lung Cancer","enrollment":624},{"nctId":"NCT05520619","phase":"PHASE2","title":"Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-09-15","conditions":"Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":114},{"nctId":"NCT05517135","phase":"","title":"tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-11-17","conditions":"Nasopharyngeal Carcinoma","enrollment":1000},{"nctId":"NCT06510660","phase":"PHASE2","title":"Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-04-11","conditions":"Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers","enrollment":48},{"nctId":"NCT06100497","phase":"PHASE2","title":"Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2023-10-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT04212052","phase":"PHASE2","title":"Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-07-01","conditions":"Non-small Cell Lung Cancer","enrollment":104},{"nctId":"NCT01691625","phase":"NA","title":"Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2012-09","conditions":"Esophageal Carcinoma","enrollment":50},{"nctId":"NCT00957086","phase":"PHASE3","title":"Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2009-08-13","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":710},{"nctId":"NCT06092957","phase":"PHASE3","title":"Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-09","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":504},{"nctId":"NCT04951063","phase":"PHASE1","title":"Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-06-01","conditions":"Locally Advanced Lung Carcinoma","enrollment":18},{"nctId":"NCT03871153","phase":"PHASE2","title":"Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Greg Durm, MD","startDate":"2019-08-02","conditions":"Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer","enrollment":7},{"nctId":"NCT06095167","phase":"PHASE3","title":"Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":476},{"nctId":"NCT00411138","phase":"PHASE3","title":"Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer","status":"UNKNOWN","sponsor":"Leiden University","startDate":"2006-11-23","conditions":"Endometrial Cancer","enrollment":670},{"nctId":"NCT00047008","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2002-07","conditions":"Head and Neck Cancer","enrollment":743},{"nctId":"NCT00003027","phase":"PHASE3","title":"Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-11-13","conditions":"Melanoma (Skin)","enrollment":482},{"nctId":"NCT03214003","phase":"NA","title":"Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC","status":"COMPLETED","sponsor":"Anhui Shi, MD","startDate":"2017-06-30","conditions":"Small Cell Lung Cancer Limited Stage, Radiotherapy","enrollment":235},{"nctId":"NCT02025036","phase":"PHASE3","title":"Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2014-10","conditions":"Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma","enrollment":249},{"nctId":"NCT05674305","phase":"PHASE3","title":"Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":366},{"nctId":"NCT03513042","phase":"","title":"Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck","status":"TERMINATED","sponsor":"Leiden University Medical Center","startDate":"2021-01-21","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":12},{"nctId":"NCT05622474","phase":"NA","title":"A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-11-30","conditions":"Nasopharyngeal Carcinoma","enrollment":236},{"nctId":"NCT00997906","phase":"PHASE2, PHASE3","title":"Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2009-09-15","conditions":"Head and Neck Cancer","enrollment":172},{"nctId":"NCT02143388","phase":"PHASE3","title":"Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial","status":"COMPLETED","sponsor":"Zhao Chong","startDate":"2014-03-31","conditions":"Local Advanced High Risk Nasopharyngeal Carcinoma","enrollment":180},{"nctId":"NCT01265849","phase":"PHASE3","title":"Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity","status":"COMPLETED","sponsor":"CEL-SCI Corporation","startDate":"2010-12","conditions":"Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate","enrollment":928},{"nctId":"NCT05469061","phase":"PHASE2","title":"Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma","enrollment":17},{"nctId":"NCT03834571","phase":"PHASE2","title":"Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women","status":"WITHDRAWN","sponsor":"AIDS Malignancy Consortium","startDate":"2022-05-31","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified","enrollment":""},{"nctId":"NCT03617133","phase":"PHASE2","title":"Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2016-04","conditions":"Uterine Cervical Neoplasms","enrollment":1000},{"nctId":"NCT00370890","phase":"PHASE3","title":"A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2006-09-04","conditions":"Nasopharyngeal Cancer","enrollment":104},{"nctId":"NCT02272699","phase":"PHASE2, PHASE3","title":"Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma","status":"WITHDRAWN","sponsor":"Peking University","startDate":"2014-11","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT04782765","phase":"PHASE2","title":"Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-03-20","conditions":"Disease-free Survival Rate","enrollment":59},{"nctId":"NCT03986463","phase":"","title":"CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-01","conditions":"Lung Neoplasms, Lung Cancer, Neoplasm of Lung","enrollment":40},{"nctId":"NCT04759235","phase":"","title":"Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-01-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT04453826","phase":"PHASE3","title":"Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-09-01","conditions":"Nasopharyngeal Cancer, Chemotherapy, Radiotherapy","enrollment":388},{"nctId":"NCT04502641","phase":"PHASE3","title":"Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-08-01","conditions":"Hypopharyngeal Cancer","enrollment":160},{"nctId":"NCT02986568","phase":"NA","title":"Efficacy of the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-05-10","conditions":"Cervical Cancer, Uterine Cancer","enrollment":380},{"nctId":"NCT02115464","phase":"PHASE2","title":"Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy","status":"TERMINATED","sponsor":"Ontario Clinical Oncology Group (OCOG)","startDate":"2014-12-17","conditions":"Lung Cancer","enrollment":54},{"nctId":"NCT04189094","phase":"PHASE2","title":"Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2020-01-01","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":140},{"nctId":"NCT01230996","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2010-07","conditions":"Locally Advanced Cervical Cancer","enrollment":22},{"nctId":"NCT02812641","phase":"PHASE2","title":"Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2016-06","conditions":"Stage III Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT00331760","phase":"PHASE2","title":"Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2006-03","conditions":"Cervical Cancer, Endometrial Cancer","enrollment":106},{"nctId":"NCT03328234","phase":"PHASE3","title":"Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2017-09-01","conditions":"IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer","enrollment":2},{"nctId":"NCT03308552","phase":"PHASE3","title":"Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2017-12-01","conditions":"Esophageal Neoplasms","enrollment":164},{"nctId":"NCT03656965","phase":"PHASE3","title":"EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug","status":"UNKNOWN","sponsor":"Kuwait Cancer Control Center","startDate":"2018-05-01","conditions":"Drug Use for Unapproved Schedule","enrollment":50},{"nctId":"NCT01218048","phase":"PHASE2","title":"ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Robert Ferris","startDate":"2011-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":40},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT02434614","phase":"PHASE3","title":"Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Wei Jiang","startDate":"2015-03","conditions":"Nasopharyngeal Carcinoma","enrollment":440},{"nctId":"NCT01872962","phase":"PHASE3","title":"Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-11","conditions":"Nasopharyngeal Carcinoma","enrollment":480},{"nctId":"NCT00017004","phase":"PHASE3","title":"Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2001-08","conditions":"Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma","enrollment":114},{"nctId":"NCT02526316","phase":"PHASE1","title":"Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers","status":"COMPLETED","sponsor":"Oryx GmbH & Co. KG","startDate":"2015-06","conditions":"HPV-induced Cancers","enrollment":11},{"nctId":"NCT00069953","phase":"PHASE2","title":"Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2003-09","conditions":"Esophageal Cancer","enrollment":43},{"nctId":"NCT03015727","phase":"PHASE3","title":"Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-12","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":440},{"nctId":"NCT01755845","phase":"PHASE3","title":"Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients","status":"UNKNOWN","sponsor":"xie congying","startDate":"2011-01","conditions":"Cervical Cancer","enrollment":300},{"nctId":"NCT02610010","phase":"PHASE3","title":"Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-11","conditions":"Nasopharyngeal Carcinoma","enrollment":462},{"nctId":"NCT00002550","phase":"PHASE3","title":"Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1994-03","conditions":"Lung Cancer","enrollment":429},{"nctId":"NCT00326378","phase":"PHASE3","title":"Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2005-10","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":434},{"nctId":"NCT01485731","phase":"PHASE1","title":"Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer","status":"COMPLETED","sponsor":"University of Miami","startDate":"2012-01","conditions":"Cervical Cancer","enrollment":8},{"nctId":"NCT00785421","phase":"PHASE2, PHASE3","title":"Chemotherapy With or Without Enoxaparin in Pancreatic Cancer","status":"COMPLETED","sponsor":"CONKO-Studiengruppe","startDate":"2004-04","conditions":"Pancreatic Cancer","enrollment":312},{"nctId":"NCT00012012","phase":"PHASE1, PHASE2","title":"Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2001-08","conditions":"Cervical Cancer, Radiation Toxicity","enrollment":45},{"nctId":"NCT02047487","phase":"","title":"After Induction Chemotherapy of DP Plus DDP Concurrent Radiotherapy With and Without Bevacizumab Study","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2013-05","conditions":"Head and Neck Neoplasms","enrollment":120},{"nctId":"NCT00039039","phase":"PHASE3","title":"Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2000-02","conditions":"Lung Cancer","enrollment":300},{"nctId":"NCT01945879","phase":"PHASE1, PHASE2","title":"Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer","status":"COMPLETED","sponsor":"CONKO-Studiengruppe","startDate":"2003-01","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT01854203","phase":"PHASE2, PHASE3","title":"Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-07","conditions":"Nasopharyngeal Carcinoma","enrollment":300},{"nctId":"NCT00113399","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery","status":"TERMINATED","sponsor":"Radiation Therapy Oncology Group","startDate":"2005-04","conditions":"Head and Neck Cancer","enrollment":15},{"nctId":"NCT00113386","phase":"PHASE3","title":"Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Radiation Therapy Oncology Group","startDate":"2005-04","conditions":"Lung Cancer","enrollment":19},{"nctId":"NCT00055887","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2002-11","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT00020709","phase":"PHASE3","title":"Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-06","conditions":"Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer","enrollment":840},{"nctId":"NCT00128817","phase":"PHASE3","title":"Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers","status":"TERMINATED","sponsor":"Tata Memorial Hospital","startDate":"2005-05","conditions":"Larynx Neoplasms","enrollment":900},{"nctId":"NCT00268372","phase":"PHASE3","title":"S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2005-12","conditions":"Head and Neck Cancer","enrollment":6},{"nctId":"NCT01262183","phase":"PHASE2","title":"Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2011-01","conditions":"Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus","enrollment":4},{"nctId":"NCT01418859","phase":"","title":"Clinical Study in Post-operation Treatment of Cervical Cancer","status":"UNKNOWN","sponsor":"Xi'an Jiaotong University","startDate":"2011-08","conditions":"Cervical Cancer","enrollment":183},{"nctId":"NCT00522886","phase":"PHASE1","title":"Phase I Cetuximab and Concurrent Radio-chemotherapy","status":"COMPLETED","sponsor":"Maastricht Radiation Oncology","startDate":"2007-04","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT00436293","phase":"PHASE2","title":"Taxotere + Cisplatin in Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-12","conditions":"Nasopharyngeal Neoplasms","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"without concurrent cisplatin chemotherapy","genericName":"without concurrent cisplatin chemotherapy","companyName":"Fujian Cancer Hospital","companyId":"fujian-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin is a small molecule used in chemotherapy for various cancer types, including Larynx Neoplasms, Locally Advanced Nasopharyngeal Carcinoma, Nasopharyngeal Carcinoma, Head and Neck Neoplasms, and Stage III Esophageal Squamous Cell Carcinoma. Cisplatin is administered as part of concurrent chemoradiation, which involves combining chemotherapy with radiation therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}